Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Polyana M. d'Albuquerque
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir
AIDS Research and Human Retroviruses
Virology
Infectious Diseases
Immunology
Related publications
Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
New England Journal of Medicine
Medicine
Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project
Infection and Drug Resistance
Infectious Diseases
Pharmacology
Differential Effects of Tenofovir/Emtricitabine and Abacavir/Lamivudine on Human Leukocyte Recruitment
Antiviral Therapy
Infectious Diseases
Pharmacology
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study
Antiviral Therapy
Infectious Diseases
Pharmacology
No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients
PLoS ONE
Multidisciplinary
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-positive Patients Ingesting Dabigatran
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Cost-Effectiveness Analysis of Tenofovir/Emtricitabine and Abacavir/Lamivudine in Combination With Efavirenz or Atazanavir/Ritonavir for Treatment-Naive Adults With Hiv-1 Infection in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections With Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
